Analysts expect Biodexa Pharmaceuticals Plc to report revenue of 1.36 M for 2021, against a range of 1.31 M to 1.42 M. The most recent reported year, 2025, came in at 0.00.
| Metric | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 474,900.00 | - | 473,720.00 | 0.00 | 0.00 | - | ||
| High Estimate | 1.47 M | 1.42 M | 530,933.43 | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 1.21 M | 1.31 M | 489,059.65 | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 1.34 M | 1.36 M | 509,996.54 | 0.00 | 0.00 | 0.00 |
Analysts expect Biodexa Pharmaceuticals Plc to report earnings per share of -7,409,542.25 for 2021, against a range of -7,742,045.46 to -7,077,039.04. The most recent reported year, 2025, came in at 0.00, a 100.0% beat against the -0.03 consensus.
| Metric | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -7,200,000.00 | - | -1.24 | -0.07 | 0.00 | - | ||
| High Estimate | -6,861,387.92 | -7,077,039.04 | -0.37 | -0.03 | -0.03 | 0.00 | ||
| Low Estimate | -7,757,916.78 | -7,742,045.46 | -0.39 | -0.03 | -0.03 | 0.00 | ||
| Consensus Estimate | -7,309,652.35 | -7,409,542.25 | -0.38 | -0.03 | -0.03 | 0.00 |